Dextroamphetamine Sulfate NDC 0555-0952

NDC codes

FDA NDC Directory

Product NDC (as listed)0555-0952Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00555-0952Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0555-0952-02	00555095202	100 TABLET in 1 BOTTLE (0555-0952-02)Marketed from Feb 12, 2001

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dextroamphetamine Sulfate
Generic name (nonproprietary): dextroamphetamine sulfate
Active ingredients: Dextroamphetamine sulfate — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040361
Marketing start: Feb 12, 2001
Listing expires: Dec 31, 2027
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 0555-0952_05934bca-3ed9-4ce3-ba1d-2063930aad63SPL ID 05934bca-3ed9-4ce3-ba1d-2063930aad63SPL set ID ec2d13f3-d14f-47e4-abe9-7763f95a8e94RxCUI 884385, 884386UNII JJ768O327N
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400555095202 followed by a unit qualifier and the quantity

Package 00555-0952-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 21, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Dextroamphetamine Sulfate Tablets are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft)…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040361

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040361
Product	Strength	Form · route	Labeler	Product NDC
Dextroamphetamine Sulfate	Dextroamphetamine sulfate 10 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0555-0953